Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Jan E Ehlert"'
Publikováno v:
Discover Oncology, Vol 14, Iss 1, Pp 1-16 (2023)
Abstract Background Glioblastoma multiforme (GBM) is the most aggressive primary brain tumor with poor prognosis. GMB are highly recurrent mainly because of radio- and chemoresistance. Radiotherapy with Temozolomide (TMZ) is until today the golden st
Externí odkaz:
https://doaj.org/article/7012fe8fc5b94fe288b047c578a19fa0
Autor:
Carla Castro, Philipp Metzger, Daniel Feger, Sarah Ulrich, Oliver Siedentopf, Jan E. Ehlert, Holger Weber
Publikováno v:
Cancer Research. 83:4419-4419
With the development and approval of cutting-edge immune-based approaches for cancer treatment in recent years, the global immune-oncological (IO) pipelines have dramatically increased. To overcome the challenges of rising treatment resistance, new s
Autor:
Christoph Schächtele, Jan E. Ehlert, Ruben Gerardus George Leenders, Daniel Müller, Daniel Feger, Danny C. Lenstra, Jasmin Mecinović, Federica Trivarelli, Remco Zijlmans, Gerhard Müller, Bart van Bree, Anita Wegert, Marc van de Sande, Eddy Damen, Carolin Heidemann-Dinger, Michael H.G. Kubbutat
Publikováno v:
Bioorganic & Medicinal Chemistry Letters, 29, 2516-2524
Bioorganic & Medicinal Chemistry Letters, 29, 17, pp. 2516-2524
Bioorganic & Medicinal Chemistry Letters, 29, 17, pp. 2516-2524
Detailed structure activity relationship of two series of quinazoline EHMT1/EHMT2 inhibitors (UNC0224 and UNC0638) have been elaborated. New and active alternatives are presented for the ubiquitous substitution patterns found in literature for the li
Publikováno v:
Cancer Research. 82:2893-2893
Bispecific antibodies are being explored as a means to modulate responses of the immune system to tumor infiltration. They are emerging as a growing class of immunotherapies with potential to further improve clinical efficacy and safety. Besides tumo
Autor:
Laura M. Jordt, Frank Totzke, Joachim Lauterwasser, Jan E. Ehlert, Koen Hekking, Bas Aerts, Cynthia Obodozie, Holger Weber, Gerhard Müller, Michael H. Kubbutat
Publikováno v:
Cancer Research. 82:2318-2318
CDK8 has been identified as being frequently upregulated in various types of human cancer such as colorectal cancer, certain sub-types of breast cancer and acute myeloid leukemia. In different tumor cell lines RNA interference mediated knockdown of C
Autor:
Vincent Vuaroqueaux, Oliver Siedentopf, Sarah Ulrich, Anne-Lise Peille, Sebastian Dempe, Daniel Feger, Hoor Al-Hasani, Heinz-Herbert Fiebig, Jan E. Ehlert
Publikováno v:
Cancer Research. 81:1027-1027
Testing novel anti-cancer agents across large panel of tumor models covering genetic diversity of cancers is increasingly considered as a cornerstone of preclinical development. For this purpose, Reaction Biology developed “ProLiFiler” a standard
Autor:
Holger Weber, Claude Gardin, Hanane Djamai, Renaud Prudent, Jan E. Ehlert, Thorsten Braun, Mélanie Dupont, Fabrice Paublant, Jeannig Berrou, Anna Kaci, André Baruchel, Hervé Dombret
Publikováno v:
Leukemia Research. 100:106490
Patients with FLT3-ITD mutated (FLT3-ITD+) Acute Myeloid Leukemia (AML), have frequently relapsed or refractory disease and FLT3-ITD+ inhibitors have limited efficacy. Rho kinases (ROCK) are constitutively activated by FLT3-ITD+ in AML via PI3 kinase
Autor:
Donald Bunjes, Sebastian Halbach, Dietmar Pfeifer, Philipp Hemmati, Robert S. Negrin, Fabio Ciceri, Jean-Yves Cahn, Markus Ditschkowski, Pavan Reddy, Kathrin Hanke, Daniela Dörfel, Susan Klaeger, Jürgen Finke, Zehan Hu, Gabriele Ihorst, Gérard Socié, Sanaz Taromi, Andreas Hochhaus, Glen A Kennedy, Omid Shah, Andreas Neubauer, Robert Thimme, Michael Schultheiss, Sabine Spath, Dietrich W. Beelen, Sandra Duquesne, Arnim Weber, Geoffrey R. Hill, Ronjon Chakraverty, Jürgen Kuball, Guido Kobbe, Nikolas von Bubnoff, Andrea S. Henden, Betul Oran, Burkhard Becher, Bernhard Kuster, Christoph Rummelt, Lena Osswald, Hartmut Bertz, Wolfgang Bethge, Eva-Maria Wagner, Arnon Nagler, Eliana Ruggiero, Saar Gill, Miguel Waterhouse, Andreas Mackensen, Dominik Bettinger, Francis Baumgartner, Florian Kuchenbauer, Anita Sarma, Takanori Teshima, Erika L. Pearce, Antonia M.S. Müller, Kathleen Stabla, John M. Magenau, Evelyn Ullrich, Nicolaus Kröger, Georg Häcker, Simone Thomas, Myriam Labopin, Ghulam J. Mufti, Jan E. Ehlert, Lutz P. Müller, Marie Follo, Dominik Wolf, Tony Andreas Müller, Michael Lübbert, Jacqueline Schnell, Christof Scheid, Takeshi Kondo, Donal P. McLornan, Thomas Pabst, Konrad Wilhelm, Chiara Bonini, Wolf Rösler, Simon Richardson, Cordula A. Jilg, Andrea Schmidts, Luca Vago, Joseph H. Antin, Annette Schmitt-Graeff, Yakup Tanriver, Michael A. Caligiuri, Wolfgang Herr, Kai-Li Yan, Lukas Braun, Daniel J. Weisdorf, Katayoun Rezvani, Giang Lam Vuong, Tilman Brummer, Stephan Meckel, Ralph Wäsch, Geoffroy Andrieux, Soroush Doostkam, Hauke Busch, Dennis Dong Hwan Kim, Sabine Gerull, Bruce R. Blazar, Robert Zeiser, Merav Bar, Flore Sicre-de-Fontbrune, Daniel Feger, Melanie Börries, Wolfgang Melchinger, Petya Apostolova, C. Leiber, Udo Holtick, Walter J.F.M. van der Velden, Renate Arnold, Rainer Claus, Justus Duyster, Nimitha R. Mathew, David O’Sullivan, Alexandros Spyridonidis, S K Metzelder, Thomas Schroeder, Jörg Halter, Johanna Haag, Friedrich Stölzel, Christoph Schmid, Anna Lena Illert, Claudia Lengerke, Björn Hackanson, Joern Dengjel, Francis Ayuk, Rainer Ordemann, Sonia Tugues, Marco Prinz, Inken Hilgendorf, Andreas Burchert
Publikováno v:
Nature Medicine
Nature Medicine, 24, 282-291
Nature Medicine, 24, 3, pp. 282-291
Nature Medicine, 24, 282-291
Nature Medicine, 24, 3, pp. 282-291
Contains fulltext : 190745.pdf (Publisher’s version ) (Closed access) Individuals with acute myeloid leukemia (AML) harboring an internal tandem duplication (ITD) in the gene encoding Fms-related tyrosine kinase 3 (FLT3) who relapse after allogenei
Autor:
Marianne Birkle, Ralph Graeser, Sarah Umber, Christoph Schaechtele, Frank Totzke, Daniel Müller, Kurt Ballmer-Hofer, Daniel Feger, Oliver Siedentopf, Alexandra Ortiz, Holger Weber, Constance Ketterer, Michael H.G. Kubbutat, Jan E. Ehlert, Melanie Müller
Publikováno v:
Journal of biomolecular screening
Many receptor tyrosine kinases (RTKs) represent bona fide drug targets in oncology. Effective compounds are available, but treatment invariably leads to resistance, often due to RTK mutations. The discovery of second-generation inhibitors requires ce
Autor:
Michael H.G. Kubbutat, Bassam A. Abu Thaher, Christoph Schächtele, Pierre Koch, Frank M. Boeckler, Martina Arnsmann, Frank Totzke, Stefan Laufer, Markus O. Zimmermann, Jan E. Ehlert
Publikováno v:
Journal of Medicinal Chemistry. 55:961-965
In the course of searching for new p38α MAP kinase inhibitors, we found that the regioisomeric switch from 3-(4-fluorophenyl)-4-(pyridin-4-yl)-1-(aryl)-1H-pyrazol-5-amine to 4-(4-fluorophenyl)-3-(pyridin-4-yl)-1-(aryl)-1H-pyrazol-5-amine led to an a